Partnership Opportunities
Want to Partner With Us in 2025?
Thanks to Sarepta’s recent approval there is a huge amount of excitement and investment in the gene therapy for muscular disorders space and this provides a unique opportunity for pre-clinical CROs, muscular disease model providers and clinical CROs to establish themselves as the leading commercial partners for the companies who are driving.
Partner with the Annual Gene Therapy for Muscular Disorders Summit to influence the rapidly growing landscape, increase brand awareness, demonstrate expertise and solidify yourself as a key expert in the space in front of the gene therapy community.
100+ Biotech and Pharma individuals have united previously at Gene Therapy for Muscular Disorders Summit. From extensive research with these organisations, we know they are seeking to collaborate with companies who can help them solve their problems and need reliable companies with expertize in:
-
- Rodent, canine or other large animal muscular models
- Non-human primate models for preclinical safety studies
- In vivo/in vitro artificial translational muscle models
- Preclinical CRO research services with muscular disorders or gene therapy experience
- Imaging, digital and blood-based biomarker expertize in Duchenne’s, Limb-Girdle, or Myotubular Myopathy
- AI and movement technology for remote clinical monitoring
- Advanced muscle biopsy technology
- Clinical CRO with expertise in gene therapy or muscular disorders
Our 2024 Partners
Expertise Partner
Innovation Partner
Hosting Partner
CYTOO is a drug discovery biotech company focusing on disorders affecting muscle health. CYTOO pioneered MyoScreen™, an in vitro R&D platform that enables testing muscle therapies in primary patient derived skeletal muscle cells. Using innovative, image-based, high throughput assays and quantitative functional assays, MyoScreen aids therapeutic discovery at all stages, from target identification to the development of clinical candidate potency assays. Through R&D partnerships, CYTOO has worked on more than 50 projects comprising RNA and gene therapies. To better support CMC related activities, CYTOO is establishing a GMP environment that will be operational in 2023.
Curi Bio’s preclinical discovery platform combines human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data to accelerate the discovery, safety testing, and efficacy testing of new drugs. These products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models. By offering this highly predictive platform, Curi is closing the gap between preclinical data and human-relevant results—accelerating the development of safer, more effective medicines.
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA approved treatments and product candidates in development. With a deep history in genetics – including groundbreaking mouse genetics to create Regeneron’s proprietary VelociSuite® technologies – and multiple genetic-based therapeutics in clinic, Regeneron is expanding these efforts to pursue genetics medicines in-house.
Media Partners:
CYTOO is a drug discovery biotech company focusing on disorders affecting muscle health. CYTOO pioneered MyoScreen™, an in vitro R&D platform that enables testing muscle therapies in primary patient derived skeletal muscle cells. Using innovative, image-based, high throughput assays and quantitative functional assays, MyoScreen aids therapeutic discovery at all stages, from target identification to the development of clinical candidate potency assays. Through R&D partnerships, CYTOO has worked on more than 50 projects comprising RNA and gene therapies. To better support CMC related activities, CYTOO is establishing a GMP environment that will be operational in 2023.
Experts Need Your Help With:
- Rodent, canine or other large animal muscular models
- Non-human primate models for preclinical safety studies
- Preclinical CRO research services with muscular disorders or gene therapy experience
- Imaging, digital and blood-based biomarker expertize in Duchenne’s, Limb-Girdle, or Myotubular Myopathy
- AI and movement technology for remote clinical monitoring
- Advanced muscle biopsy technology
- Clinical CRO with expertise in gene therapy or muscular disorders
Why Partner in 2025?
Meet & Network with Industry Pioneers: Connect with the experts developing gene therapies for muscular disorders to understand the needs of those at the forefront of the market.
Gain Brand Visibility: Broaden your company’s exposure and display your cutting-edge models and services that can help make the development of gene therapies for muscular disorders easier for our speakers and delegates from leading developers with a booth exhibit
Demonstrate your proficiency: Enhance your on-site presence with by giving a talk on the agenda and establish yourself as a thought leader, with the chance to give a talk, conduct a workshop, or lead an informative session in front of an audience full of influential decision-makers in the world of gene therapies for muscular disorders